Combined administration of bone marrow and anticeramide antibodies

By administering hematopoietic cell populations to patients in combination with anti-ceramide antibodies, regulating bone marrow cell populations, and blocking ceramide signal transduction or endothelial cell platforms, the problems of large cell volume and high risk in traditional HSCT are solved, thereby improving the hematopoietic cell engraftment effect and accelerating patient recovery.

CN122295369APending Publication Date: 2026-06-26MEMORIAL SLOAN KETTERING CANCER CENT +2
View PDF 34 Cites 0 Cited by

Patent Information

Application Number
CN202480075826.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-10-04
Filing Date
2024-10-04
Publication Date
2026-06-26

AI Technical Summary

Technical Problem

Traditional hematopoietic stem cell transplantation (HSCT) requires a large number of cells and carries high risks, leading to significant morbidity and mortality. There is an urgent need to improve the efficiency of HSCT and reduce the amount of hematopoietic stem cells used.

Method used

By administering hematopoietic cell populations to patients in combination with anti-ceramide antibodies or their antigen-binding fragments, the patient's natural bone marrow cell population is modulated, blocking the ceramide signaling pathway or inhibiting the formation of ceramide-rich platforms in endothelial cells, thereby reducing the dosage of hematopoietic cells.

Benefits of technology

It improves the effectiveness of hematopoietic cell engraftment, reduces the amount of hematopoietic cells used, decreases the risk of graft-versus-host disease, and improves patient survival rate and blood cell recovery speed.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN122295369A_ABST
    Figure CN122295369A_ABST
Patent Text Reader

Abstract

This disclosure provides: (i) a method of using an anticeramide antibody or an antigen-binding fragment thereof to improve hematopoietic stem cell transplantation for the treatment of various non-malignant and malignant diseases; and (ii) a composition for such treatment.
Need to check novelty before this filing date? Find Prior Art

Citation Information

Patent Citations

  • Anti-ceramide antibodies

    US10450385B2

  • Commissioning in multi-hop networks by using a single-hop connection

    US11191125B2

  • Ultra high affinity neutralizing antibodies

    US20020164326A1

  • Polypeptide Heterodimers and Uses Thereof

    US20130095097A1

  • Heterodimer Binding Proteins and Uses Thereof

    US20130129723A1